Good article, I’d add that the side effects of chronic multi-year administration of this class, has yet to be fully fleshed out (although the statins are, by and large, pretty safe for most people). Also the Novo trial for Semaglutide in Alzheimer’s Disease failed recently although I’ve only seen top-line data).
Thanks, good points, and yes, I actually wanted to include Alzheimer's trial failure in the article -- had it in literature research notebook -- but just forgot eventually due to the sheer amount of data I had to process and comprehend to craft a bird's eye view story... To the point of what's next, I think a lot is in combination therapies and different creative ways to modulate incretine biology. One really interesting example is a recent preclinical story by Insilico Medicine, here it is if you are interested: https://www.biopharmatrend.com/artificial-intelligence/beyond-glp-1-a-new-combination-strategy-shows-up-to-313-in-preclinical-study-1487/
Good article, I’d add that the side effects of chronic multi-year administration of this class, has yet to be fully fleshed out (although the statins are, by and large, pretty safe for most people). Also the Novo trial for Semaglutide in Alzheimer’s Disease failed recently although I’ve only seen top-line data).
Thanks, good points, and yes, I actually wanted to include Alzheimer's trial failure in the article -- had it in literature research notebook -- but just forgot eventually due to the sheer amount of data I had to process and comprehend to craft a bird's eye view story... To the point of what's next, I think a lot is in combination therapies and different creative ways to modulate incretine biology. One really interesting example is a recent preclinical story by Insilico Medicine, here it is if you are interested: https://www.biopharmatrend.com/artificial-intelligence/beyond-glp-1-a-new-combination-strategy-shows-up-to-313-in-preclinical-study-1487/